1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Authors:
  • YJY.Y. Janjigian
    Y.Y. Janjigian
  • AKA. Kawazoe
    A. Kawazoe
  • YBY. Bai
    Y. Bai
  • JXJ. Xu
    J. Xu
  • SLS. Lonardi
    S. Lonardi
  • JMJ-P. Metges
    J-P. Metges
  • PWP.E. Yanez Weber
    P.E. Yanez Weber
  • LWL.S. Wyrwicz
    L.S. Wyrwicz
  • LSL. Shen
    L. Shen
  • YOY.V. Ostapenko
    Y.V. Ostapenko
  • MBM. Bilici
    M. Bilici
  • HCH.C. Chung
    H.C. Chung

Abstract
No abstract available